Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The experimental group (Group 1) will receive 1% voriconazole eye drop (Aurolab, Madurai, India) + 5% Natamycin ophthalmic suspension eye drop hourly (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).
The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.
Patients will be followed up every week after being discharged until complete resolution is noted.

Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The placebo group (Group 2) will receive Vehicle eye drops + 5% Natamycin ophthalmic suspension every hour (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).
The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.
Patients will be followed up every week after being discharged until complete resolution is noted.

Infection, Fungal

Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops

GMRV Campus LV Prasad Eye Insitute

Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis

Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis: a Prospective Randomized Double Masked Clinical Trial

Primary End point:
Complete success: Complete resolution of the infiltrate with formation of a scar on medical treatment alone Partial success: Complete resolution of the infiltrate on medical treatment and use of cyanoacrylate glue and bandage contact lens Failure: Worsening of the ulcer necessitating therapeutic penetrating keratoplasty or evisceration

improvement in best corrected visual acuity

Charitha

L.V. Prasad Eye Institute

Patients presenting with bacterial keratitis. These patients will be treated with besifloxacin ophthalmic suspesnion 0.6%, initially 6x a day and tapered down as the patient's condition improves based on the clinical judgement of the treating physician.

Patients presenting with bacterial keratitis. These patients will be treated initially with fortified cefazolin and vancomycin drops every 1 hour around the clock (24hours) for a minimum of 48 hours, and will subsequently have their dosages tapered gradually by the treating physician as is the standard of care for bacterial keratitis.

Bacterial Keratitis

Besifloxacin

Fortified Tobramycin and Cefazolin eye drops

Tobramycin and Cefazolin

McGill Academic Eye Center

Besifloxacin in Bacterial Keratitis

Besifloxacin Ophthalmic Suspension in Patients With Bacterial Keratitis: A Prospective, Randomized Clinical Study

We will take repeat cultures and determine when no more bacteria can be cultured

Jean Deschenes

Professor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Patients randomized to gatifloxacin (Zymar)

Patients randomized to moxifloxacin (Vigamox)

Patients randomized to ofloxacin (Ocuflox)

Patients randomized to azithromycin (AzaSite)

Age-related Macular Degeneration

Conjunctival and nasopharyngeal bacteria cultures

agar/atrofi

Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis

Besifloxacin in Bacterial Keratitis

Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics

A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı